| Business Summary | | Genaera
Corporation
is
a
biopharmaceutical
company
committed
to
developing
medicines
for
serious
diseases
from
genomics
and
natural
products.
Its
research
and
development
efforts
are
focused
on
anti-angiogenesis,
obesity,
infectious
diseases
and
respiratory
diseases.
Squalamine
is
the
Company's
lead
product
development
candidate
and
is
being
evaluated
in
clinical
studies
for
the
treatment
of
solid
tumors. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Genaera
Corporation
is
a
biopharmaceutical
company
with
research
and
development
efforts
in
anti-angiogenesis,
respiratory
genomics
and
infectious
disease.
For
the
six
months
ended
6/30/01,
revenues
totaled
$250
thousand
vs.
none.
Net
loss
applicable
to
Common
increased
4%
to
$5.7
million.
Revenues
reflect
a
research
collaboration
and
licensing
agreement
with
MedImmune.
Higher
loss
reflects
higher
manufacturing
expenses
and
the
hiring
of
additional
personnel. | More
from
Market Guide: Significant
Developments |
| | | | FY2000 Pay | |
| Michael Dougherty, 43 Chairman | $378K | Roy Levitt, M.D., 47 Pres,
CEO, Director | 354K | Christopher Schnittker, 32 CFO,
VP | 61K | Kenneth Holroyd, M.D., 42 Exec.
VP and CBO | 294K | Sean Johnston Ph. D., 42 VP,
Manufacturing | 160K | Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|